Bristol-Myers Squibb (BMY +0.7%) has filed a lawsuit in a New Jersey court against Dr. Reddy’s Laboratories (RDY -0.6%)
in an attempt to block the commercial entry of the latter’s generic
version of leukemia med Sprycel (dasatinib). It claims that RDY’s
product infringes on two patents that expire in 2025 and 2026,
respectively.
Sprycel accounted for 8.5% ($1,003M) of BMY’s H1 product sales of $11,744M.
https://seekingalpha.com/news/3504307-bristol-myers-sues-dr-reddys-block-generic-sprycel
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.